WINT (Windtree Therapeutics) Cyclically Adjusted PB Ratio: (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Windtree Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Windtree Therapeutics  (OTCPK:WINT) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Windtree Therapeutics Cyclically Adjusted PB Ratio Related Terms


Windtree Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Windtree Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Windtree Therapeutics Cyclically Adjusted PB Ratio Chart

Windtree Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.05 0.01 0.00 0.00 0.00

Windtree Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

WINT vs LIPO, ITRMF, IOBTQ: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Windtree Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Windtree Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Windtree Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Windtree Therapeutics's Cyclically Adjusted PB Ratio falls into.



Windtree Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Windtree Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2025 is calculated as:

For example, Windtree Therapeutics's adjusted Book Value per Share data for the three months ended in Sep. 2025 was:

Adj_Book=Book Value per Share/CPI of Sep. 2025 (Change)*Current CPI (Sep. 2025)
=-0.345/324.8000*324.8000
=-0.345

Current CPI (Sep. 2025) = 324.8000.

Windtree Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201512 2,723,568.517 236.525 3,740,048.850
201603 -1,632,681.179 238.132 -2,226,894.525
201606 -4,956,247.334 241.018 -6,679,124.107
201609 -7,278,762.260 241.428 -9,792,327.245
201612 -8,923,059.896 241.432 -12,004,249.040
201703 -7,252,129.750 243.801 -9,661,534.378
201706 -8,222,408.445 244.955 -10,902,566.851
201709 -6,505,466.099 246.819 -8,560,829.551
201712 -1,000,551.215 246.524 -1,318,245.017
201803 -1,173,974.623 249.554 -1,527,953.700
201806 -1,016,649.134 251.989 -1,310,404.973
201809 -1,122,275.483 252.439 -1,443,972.908
201812 286,164.875 251.233 369,960.759
201903 264,205.111 254.202 337,581.215
201906 244,384.275 256.143 309,889.447
201909 222,579.681 256.759 281,563.179
201912 246,187.585 256.974 311,166.607
202003 230,266.182 258.115 289,756.333
202006 222,632.028 257.797 280,495.439
202009 201,378.640 260.280 251,297.765
202012 184,962.523 260.474 230,640.400
202103 156,794.372 264.877 192,265.890
202106 95,652.015 271.696 114,347.559
202109 84,557.237 274.310 100,120.997
202112 66,668.433 278.802 77,667.689
202203 54,894.445 287.504 62,015.540
202206 29,376.996 296.311 32,201.465
202209 24,011.607 296.808 26,276.145
202212 11,668.967 296.797 12,769.942
202303 6,959.306 301.836 7,488.777
202306 2,028.585 305.109 2,159.505
202309 1,308.336 307.789 1,380.646
202312 508.940 306.746 538.894
202403 1,511.341 312.332 1,571.672
202406 295.147 314.175 305.128
202409 94.192 315.301 97.030
202412 38.986 315.605 40.122
202503 2.894 319.799 2.939
202506 0.390 322.561 0.393
202509 -0.345 324.800 -0.345

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Windtree Therapeutics Business Description

Address 2600 Kelly Road, Suite 100, Warrington, PA, USA, 18976-3622
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.